{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-25-000069","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.817810+00:00","generated_at":"2026-05-17T20:51:20.133377+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026","bullets":["Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.","Cash, equivalents and marketable securities $212.9M as of June 30, 2025; runway into 2027.","PROSERA Phase 3 PAH study enrolled 390 patients; topline results expected February 2026.","SERANATA Phase 3 PH-ILD study first site activations planned Q4 2025; 480-patient, 24-week trial.","Collaboration revenue $11.5M (mostly cost reimbursement from Chiesi) vs $95.8M in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-25-000069","json":"https://secwatch.observer/filing/0001728117-25-000069.json","markdown":"https://secwatch.observer/filing/0001728117-25-000069.md","text":"https://secwatch.observer/filing/0001728117-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/0001728117-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/goss-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:51:20.133377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}